Currently recruiting studies

 

B3 & Glaucoma – CERA

There is a trial being undertaken by CERA which is investigating the role of B3 for Glaucoma.  At this stage there is some evidence that B3 can be of helpful in mice, however this has not been proved in humans.  As this is a trial, we do not know what dose of B3 is being recommended or if B3 is helpful or harmful to the eye and therefore cannot provide advice.  More information can be obtained by contacting CERA and registering to be part of the trial.

Website: www.cera.org.au  Phone: 9929 8360

 

Retina responses to light

Help researchers find out more.

Researchers at Eye Surgery Associates are looking for volunteers to study responses of the retina to light.

To be eligible you will need to be:
• Aged 18 – 55 years
• Healthy
• Normal vision or normal vision wearing prescription glasses
• Able to attend one two-hour testing session in East Melbourne

You will be paid $20 to assist with out of pocket expenses.

To find out more information email Dr Heather Mack – hmack@eyesurgery.com.au

This study is being conducted by Dr Heather Mack of Eye Surgery Associates, 2/232 Victoria Pde, East Melbourne 3002 phone 03 9416 0695 and has been approved by Royal Australian and New Zealand College of Ophthalmologists Human Research Ethics Committee.

 

Genetic susceptibility to hydroxychloroquine (Plaquenil) retinal toxicity

Researchers at Melbourne Health, Walter and Eliza Hall Institute and Eye Surgery Associates are looking for volunteers who are receiving hydroxychloroquine (Plaquenil) treatment for rheumatologic and dermatologic conditions including rheumatoid arthritis, systemic lupus erythematosis, discoid lupus erythematosis and psoriasis to investigate genetic susceptibility to retinal toxicity.

To be eligible participants need to be aged 18 years or older and:
• Receiving hydroxychloroquine treatment
• Have the ability to attend a two-hour testing session in inner Melbourne

Both participants with retinal toxicity (cases) and with no retinal toxicity (controls) are being recruited.

Participants will be paid $20 to assist with out of pocket expenses.

To find out more information contact Dr Heather Mack – hmack@eyesurgery.com.au

This study is being conducted by Dr Heather Mack of Melbourne Health at Eye Surgery Associates, 2/232 Victoria Pde, East Melbourne 3002 phone 03 9416 0695.

This study has received ethical approval from the Melbourne Health Human Research Ethics Committee.

Patients who are treated with hydroxychloroquine for rheumatic conditions (including rheumatoid arthritis and SLE) and skin conditions (including discoid lupus ) can rarely develop damage to the retina. Retinal damage is known to be related to dose of hydroxychloroquine, but it is not possible to predict susceptibility of individual patients to retinal damage. The purpose of the study is to identify variations in genes that predict retinal damage from hydroxychloroquine (either making it worse, or, reducing the effect). This study has been approved by Melbourne Health Human Research Ethics Committee.

 

Ivabradine (Coralan) and retinal function

Help researchers find out more.

Researchers at Eye Surgery Associates are looking for volunteers who are taking ivabradine (Coralan) to study effects of ivabradine on responses of the retina to light.

To be eligible you will need to be:
• Aged over 18 years
• Prescribed ivabradine by your cardiologist
• Able to attend one two-hour testing session in East Melbourne

You will be paid $20 to assist with out of pocket expenses.

To find out more information email Dr Heather Mack – hmack@eyesurgery.com.au

This study is being conducted by Dr Heather Mack of Eye Surgery Associates, 2/232 Victoria Pde, East Melbourne 3002 phone 03 9416 0695 and has been approved by Royal Australian and New Zealand College of Ophthalmologists Human Research Ethics Committee.

Completed studies

Novartis Pharmaceuticals: RIVAL STUDY

Development of new geographic atrophy in patients with neovascular (wet) age-related macular degeneration: a comparison of ranibizumab and aflibercept.